论文部分内容阅读
目的评价卡培他滨联合奥沙利铂方案治疗晚期大肠癌的疗效与毒副反应。方法26例晚期结直肠癌患者均采用卡培他滨联合奥沙利铂治疗,具体方法为:希罗达片1250mg/m2,2次/d,第1～14d口服,休息7d;奥沙利铂注射剂100mg/m2,第1d静滴,维持2h。21d为1个疗程,每例患者至少化疗2个疗程。通过RECIST标准评价患者治疗后的疗效,通过NCI标准观察治疗过程中出现的不良反应。结果26例患者中可评价疗效:CR0例,PR12例,SD11例,PD3例,总有效率46%(12/26)。初治患者有效率75%(3/4),复治患者有效率41%(9/22)。主要不良反应有厌食乏力(60%)、皮肤色素沉着(38%)、神经毒性(50%)、手足综合征(30%)、腹泻(24%)、恶心呕吐(16%)、肝功损害(19%)、白细胞下降(10%)。但症状较轻,均可耐受。结论卡培他滨联合奥沙利铂方案疗效肯定,用药方便,不良反应低,可广泛应用于晚期大肠癌的辅助化疗,特别是年老体弱和对其他化疗药物耐受性较差的患者。
Objective To evaluate the efficacy and side effects of capecitabine and oxaliplatin in the treatment of advanced colorectal cancer. Methods 26 cases of advanced colorectal cancer patients were treated with capecitabine combined with oxaliplatin, the specific method is: Xeloda tablets 1250mg / m2, 2 times / d, 1 ~ 14d oral, rest 7d; Platinum injection 100mg / m2, 1d intravenous infusion, maintaining 2h. 21d for a course of treatment, each patient at least two courses of chemotherapy. RECIST criteria were used to evaluate the efficacy of the treatment after treatment, and the adverse reactions during the treatment were observed by the NCI standard. Results The curative effect was evaluated in 26 patients: CR0, PR12, SD11 and PD3, the total effective rate was 46% (12/26). The rate of initial treatment was 75% (3/4) and that of retreatment was 41% (9/22). The main adverse reactions were anorexia (60%), skin pigmentation (38%), neurotoxicity (50%), hand-foot syndrome (30%), diarrhea (24%), nausea and vomiting (19%), leukopenia (10%). But the symptoms are mild, can be tolerated. Conclusion Capecitabine combined with oxaliplatin regimen has definite curative effect, convenient medication and low adverse reaction. It can be widely used in the adjuvant chemotherapy of advanced colorectal cancer, especially in patients who are weak and old and have poor tolerance to other chemotherapy drugs .